MD1003
Phase 3Small molecule
MD1003 is one of 70 small molecule programs targeting Adrenomyeloneuropathy. It is currently in Phase 3.
3
Indications
9
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1MD1003
MMedDay Pharmaceuticals SA
Phase 3
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Novantrone
PfizerPreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis3 trials
ESS2 trials
Cardiac Repolarization1 trial
Pilot Study1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MD1003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedDay Pharmaceuticals SA